▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4044 by analyst upside · 2026-09-28
IOVA
Iovance Biotherapeutics, Inc.
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
-2.7%
implied upside to consensus target
Current Price $11.0
Consensus Target $10.7
Bull Target $15.0
Bear Target $6.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
2
Sell
0
52-Week Low $1.76
52-Week High $11.13
YTD Return +336.5%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.69
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $325M
Profit Margin -89.1%
52-WEEK RANGE
52-Week Low $1.76
52-Week High $11.13
Current Price $11.0
Bear Target $6.0
Bull Target $15.0
● Now $11.0 ● Target $10.7
TRADING DATA
Avg Volume 16.6M
YTD Return +336.5%
Analyst Count 10
Consensus Buy
Upside to Target -2.7%
Last Updated 2026-09-28

ANALYST SUMMARY

Iovance Biotherapeutics, Inc. (IOVA) is currently trading at $11.0 with a Wall Street consensus price target of $10.7, which is 2.7% below the current price over the next 12 months. 10 analysts currently cover IOVA, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $15.0, while the most cautious has a target of $6.0.

IOVA operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 336.5% year-to-date and is currently trading near the upper end of its 52-week range of $1.76 – $11.13.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for IOVA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays - Reiterated
Overweight → Overweight 2026-09-17 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-08-25 Building track record
UBS - Reiterated
Neutral → Neutral 2026-08-20 33% win rate (6 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-08-18 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-08-07 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-08-07 Building track record
Chardan Capital - Reiterated
Buy → Buy 2026-05-08 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-04-10 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
54
out of 100
Coverage depth
18/30
Consensus clarity
14/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →